Why the study?
Do dedicated coagulation assays provide better monitoring of direct thrombin inhibitor concentrations compared to routine assays in pooled plasma?
Do dedicated coagulation assays provide better monitoring of direct thrombin inhibitor concentrations compared to routine assays in pooled plasma?
Dedicated calibrated assays based on diluted thrombin time (Hemoclot and HemosIL) are more suitable than routine coagulation tests for monitoring direct thrombin inhibitor concentrations.
May support calibrated diluted TT assays for DTI monitoring; leaves open translation from pooled plasma to clinical practice.
The use of direct thrombin inhibitors (DTIs) for prophylactic or therapeutic anticoagulation is increasing because of the predictable bioavailability and short half-life of these DTIs. However, in certain situations, indication of the concentration is warranted. We investigated the effects of 3 DTIs (lepirudin, argatroban, and bivalirudin) in 6 pooled plasma specimens on routine coagulation assays (activated partial thromboplastin time [aPTT], prothrombin time [PT], and thrombin time [TT]) and dedicated DTI assays (Hemoclot, HemosIL, the ecarin clotting time, and a chromogenic ecarin clotting time) on 2 coagulation analyzers. We found routine tests to be nondiscriminative between concentrations of different DTIs in the aPTT. Moreover, for PT and TT, the responses for different DTIs differed. This was similar for ecarin clotting assays. The Hemoclot and HemosIL assays showed identical linear increases for all 3 DTIs. We conclude that dedicated calibrated assays based on a diluted TT (Hemoclot and HemosIL) appear to be the most suitable for monitoring purposes.
No takes yet. Share an insight, caveat, or question.
Curvers et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: